Rounding out our endocrine rare disease portfolio, TransCon CNP clinical data demonstrated it could be a highly differentiated product with a unique profile that represents a major step forward in ...

The potential upside from other products like Yorvipath and TransCon CNP is seen as a counterbalance to Skytrofa's current underperformance. Ascendis Pharma's pipeline includes TransCon CNP ...

SKYTROFA has achieved a leading position in value in the U.S. growth hormone market. And for TransCon CNP, we have a clear path to submit our NDA and MAA as a differentiated treatment of ...

Founded in 1997, and under the leadership of Terry Lynch, Transcon has developed significant ocean import business from the transpacific including buyer consolidation services, less-than-container ...

SKYTROFA has achieved a leading position in value in the U.S. growth hormone market. And for TransCon CNP, we have a clear path to submit our NDA and MAA as a differentiated treatment of ...